Decoding the association between breast cancer prevalence and obesity-induced metabolic disorders
Abstract
Background: Breast cancer (BC) is the most common malignancy diagnosed among women worldwide, constituting approximately one-third of all recorded female cancers. It is also the prominent cause of cancer-related mortality among women. This study aimed to investigate the correlation between BC prevalence and certain metabolic disorders such as obesity and Insulin Resistance (IR) as well as hormonal disorders.
Methods: A cross-sectional study was conducted to identify potential metabolic risk factors that were associated with BC prevalence. The study included 203 BC patients from the breast clinics at medical and oncology centers and 80 healthy subjects (HS). BC patients were divided into four groups according to their body mass index (BMI). Baseline characteristics, Lipid profile, IR, leptin-adiponectin ratio, and Inflammatory biomarkers were evaluated in BC patients and HS
Results: Our data indicated that the highest prevalence rates of BC were observed among participants aged 40-47 years and those aged 48 years and above. 54 patients were classified as obese I (BMI 30.0-34.9), whereas 84 patients were Obese II (BMI 35.0-39.9). There was a prominent association between BC prevalence and family history, and estrogen receptor (ER) positively. Dyslipidemia and IR indices were significantly elevated in obese BC patients compared to HS. Overweight BC patients (BMI 25.0-29.9) also revealed significantly increased leptin levels, and clear decline in adiponectin levels. In addition, patients with higher BMI “had significantly increased in levels of C-Reactive Protein (CRP), IL-6, IL-1b, TNF-a, Resistin, Nesfatin-1 and Lipocalin-2.
Conclusion: BC prevalence is associated with obesity-IR axis and its consequences. Our data demonstrate that IR indices, adipokines and inflammatory biomarkers could serve as feasible predictors in oncology for monitoring the BC risk and progression in obese women.
Keywords
Breast cancer, Metabolic disorders, Insulin Resistance, Nesfatin-1, Lipocalin-2
Full Text:
PDFReferences
Glassman I, Le N, Asif A, Goulding A, Alcantara CA, Vu A, et al. The role of obesity in breast cancer pathogenesis. Cells, (2023); 12: 2061.
Mohanty SS, Mohanty PK. Obesity as potential breast cancer risk factor for postmenopausal women. Genes & Diseases, (2021); 8: 117-23.
García-Estévez L, González-Rodríguez M, Calvo I, Orta A, Gión M, Moreno-Bueno G, et al. Obesity, overweight and breast cancer: New clinical data and implications for practice. Frontiers in Oncology, (2025); 15: 1579876.
Kakkat S, Suman P, Turbat-Herrera EA, Singh S, Chakroborty D, Sarkar C. Exploring the multifaceted role of obesity in breast cancer progression. Frontiers in Cell and Developmental Biology, (2024); 12: 1408844.
Modi ND, Tan JQE, Rowland A, Koczwara B, Abuhelwa AY, Kichenadasse G, et al. The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data. npj Breast Cancer, (2021); 7: 1-6.
Ostinelli G, Laforest S, Denham SG, Gauthier MF, Drolet-Labelle V, et al. Increased adipose tissue indices of androgen catabolism and aromatization in women with metabolic dysfunction. Journal of Clinical Endocrinology & Metabolism, (2022); 107: e3330-42.
Al-Shami K, Awadi S, Khamees AA, Alsheikh AM, Al-Sharif S, et al. Estrogens and the risk of breast cancer: A narrative review of literature. Heliyon, (2023);1;9(9).
Kuryłowicz A. Estrogens in adipose tissue physiology and obesity-related dysfunction. Biomedicines, (2023); 11: 690.
Li F, Gao Z. Obesity, chronic breast inflammation and carcinogenesis: Molecular pathways and clinical implications. International Journal of Oncology, (2025); 68: 12.
Li Z, Shen G, Shi M, Zheng Y, Guan Y, et al. Association between high body mass index and prognosis of patients with early-stage breast cancer: A systematic review and meta-analysis. Cancer Pathogenesis and Therapy, (2023); 1: 205-15.
Chen J, Dalerba P, Terry MB, Yang W. Global obesity epidemic and rising prevalence of early-onset cancers. Journal of Global Health, (2024); 14: 04205.
Habanjar O, Nehme R, Goncalves-Mendes N, Cueff G, Blavignac C, et al. The obese inflammatory microenvironment may promote breast DCIS progression. Frontiers in Immunology, (2024); 15: 1384354.
Carleton N, Nasrazadani A, Gade K, Beriwal S, Barry PN, et al. Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women. The Lancet Healthy Longevity, (2022); 3: e54-66.
Simone V, D’Avenia M, Argentiero A, Felici C, Rizzo FM, et al. Obesity and breast cancer: molecular interconnections and potential clinical applications. The Oncologist, (2016); 21: 404-17.
Zangouri V, Balaneji SS, Golmoradi R, Kafili E, Bologhi S, et al. Effects of BMI on prognosis, disease-free survival and overall survival of breast cancer. BMC Cancer, (2025); 25: 257.
Ozaki Y, Masuda J, Kataoka A, Kogawa T, Abe T, et al. The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor-positive breast cancer: A single-institute retrospective study. Cancer Reports, (2023); 6: e1695.
Pan K, Chlebowski RT, Mortimer JE. Insulin resistance and breast cancer prevalence and mortality in postmenopausal women in the Women’s Health Initiative. Cancer, (2020); 126: 3638-47.
Albers FEM, Swain CTV, Lou MWC, Dashti SG, Rinaldi S, et al. Insulin and insulin-like growth factor and risk of postmenopausal estrogen receptor-positive breast cancer: A case-cohort analysis. Cancer Epidemiology, Biomarkers & Prevention, (2025); 34: 541-9.
Gholami M. FTO is a major genetic link between breast cancer, obesity, and diabetes. Breast Cancer Research and Treatment, (2024); 204: 159-69.
Ajabnoor GMA. The molecular and genetic interactions between obesity and breast cancer risk. Medicina, (2023); 59: 1338.
Chew SM, Liu B, Shen S, Iyengar NM. The role of obesity and inflammation in breast cancer recurrence. Current Breast Cancer Reports, (2024); 16: 237-50.
Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers, (2023); 15: 485.
Wu Y, Li X, Li Q, Cheng C, Zheng L. Adipose tissue-to-breast cancer crosstalk: comprehensive insights. Biochimica et Biophysica Acta – Reviews on Cancer, (2022); 1877: 188800.
Liu XZ, Pedersen L, Halberg N. Cellular mechanisms linking cancers to obesity. Cell Stress, (2021); 5: 55-72.
Verras GI, Tchabashvili L, Chlorogiannis DD, Mulita F, Argentou MI. Updated clinical evidence on the role of adipokines and breast cancer: a review. Cancers, (2023); 15: 1572.
Naif NH, Ahmed EM, Thamer NA, Muhsein OA. The impact of inflammatory and adipokine biomarkers on breast cancer progression and patient outcomes. Bulletin of Pharmaceutical Sciences Assiut University, (2025); 48: 511-22.
Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes & Metabolism Journal, (2021); 45: 285-311.
Ruan GT, Xie HL, Hu CL, Liu CA, Zhang HY, et al. Comprehensive prognostic effects of systemic inflammation and insulin resistance in women with breast cancer with different BMI: a prospective multicenter cohort. Scientific Reports, (2023); 13: 4303.
Srinivasan M, Arzoun H, Gk LB, Thangaraj SR. A systematic review: does insulin resistance affect the risk and survival outcome of breast cancer in women? Cureus, (2022); 14: e21438.
Ruan GT, Xie HL, Zhang HY, Liu CA, Ge YZ, et al. A novel inflammation and insulin resistance related indicator to predict the survival of patients with cancer. Frontiers in Endocrinology, (2022); 13: 905266.
Gamez J, Sanchez F, Ortiz-Soto G, Cox J, Gerami A, et al. Lipocalin-2 promotes breast cancer metastasis via tumor cell intrinsic and extrinsic mechanisms. Cancer Research, (2024); 84(6 Suppl): 1495.
Eknoyan G. Adolphe Quetelet (1796-1874)-the average man and indices of obesity. Nephrology Dialysis Transplantation, (2008); 23: 47-51.
Tamimi R, Colditz GA, Hankinson SE. Population attributable risk of modifiable and nonmodifiable breast cancer risk factors in postmenopausal breast cancer. American Journal of Epidemiology, (2016); 184: 884-93.
Yang Z, Sun Z. Influence of obesity on breast cancer development in relation to menopausal status. Molecular and Clinical Oncology, (2026); 24: 23.
Khan S, Rogers MA, Khurana KK, Meguid MM, Numann PJ. Estrogen receptor alpha expression in normal human breast epithelium is consistent over time. International Journal of Cancer, (2002); 102: 334-7.
Bertrand KA, Bethea TN, Adams-Campbell LL, Palmer JR. Differential patterns of risk factors for early-onset breast cancer by ER status in African American women. Cancer Epidemiology, Biomarkers & Prevention, (2017); 26: 270-7.
Chen K, Zhang J, Beeraka NM, Tang C, Babayeva YV, et al. Advances in the prevention and treatment of obesity-driven effects in breast cancers. Frontiers in Oncology, (2022); 12: 820968.
Javed SR, Skolariki A, Zameer MZ, Lord SR. Implications of obesity and insulin resistance for the treatment of estrogen receptor-positive breast cancer. British Journal of Cancer, (2024); 131: 1724-36.
Terre-Torras I, Recalde M, Diaz Y, de Bont J, Bennett M, et al. Air pollution and green spaces in relation to breast cancer risk among pre and postmenopausal women: A mega cohort from Catalonia. Environmental Research, (2022); 214: 113839.
Gearhart-Serna LM, Mills BA, Hsu H, Fayanju OM, Hoffman K, et al. Cumulative environmental quality is associated with breast cancer incidence differentially by summary stage and urbanicity. Scientific Reports, (2023); 13: 20301.
Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Research and Treatment, (2017); 165: 193-200.
Salagame U, Banks E, Sitas F, Canfell K. Menopausal hormone therapy use and breast cancer risk by receptor subtypes: results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study. PLoS One, (2018); 13: e0205034.
Baglia ML, Malone KE, Tang MT, Li CI. Alcohol, smoking, and risk of Her2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer. International Journal of Cancer, (2018); 143: 1849-57.
Mugada V, Chandrabhatla SK, Kaja LK, Kandula MR. Association between sociodemographic factors and estrogen receptor-positive, progesterone receptor-positive breast cancer subtypes: a cross-sectional study. Makara Journal of Health Research, (2020); 24: 110-16.
Fritz J, Bjørge T, Engeland A, Ghaderi S, Grotmol T, et al. Insulin resistance measured by the triglyceride-glucose index and risk of obesity-related cancers: an epidemiological investigation in more than 500,000 individuals. Journal of Clinical Oncology, (2019); 37(15 Suppl): 1552.
Abdulwahab S, Mahmoud R, Al-Rubaie R. Comparative analysis of insulin resistance markers with lipid profile parameters in a sample of Iraqi patients. OBAT: Jurnal Riset Ilmu Farmasi dan Kesehatan, (2025); 3(1): 110-19.
Wu X, Xu T, Zhao D, Shen B, Xu Y, et al. Association between triglyceride glucose index and breast cancer in 142,184 Chinese adults: findings from the REACTION study. Frontiers in Endocrinology, (2024); 15: 1321622.
Zooravar D, Radkhah H, Amiri BS, Soltani P. Association Between Triglyceride‐Glucose Index and Breast Cancer: A Systematic Review and Meta‐Analysis. Cancer Reports, (2025);8(4):e70194.
Zhao P, Xia N, Zhang H, Deng T. The metabolic syndrome is a risk factor for breast cancer: a systematic review and meta-analysis. Obesity Facts, (2020);13(4):384-96.
Matthews DR H, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, (1985);28(7):412-9.
Panigoro SS, Kurnia D, Panigoro R, Susanto H, Haryono SJ, et al. The association between triglyceride-glucose index as a marker of insulin resistance and the risk of breast cancer. Frontiers in Endocrinology, (2021); 12: 745236.
Macis D, Guerrieri-Gonzaga A, Gandini S. Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. International journal of epidemiology, (2014);43(4):1226-36.
Cairat M, Rinaldi S, Navionis AS, Romieu I, Biessy C, et al. Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort. BMC medicine, (2022);20(1):118.
Sánchez-Jiménez F, Pérez-Pérez A, de la Cruz-Merino L, Sánchez-Margalet V. Obesity and breast cancer: role of leptin. Frontiers in Oncology, (2019); 9: 596.
Muhammad UK, Sulyman SB, Saleh I, Gwarzo MY, Babagana K, et al. Association of adiponectin gene polymorphism with adipokine and lipid profile in breast cancer patients from Kano, Nigeria. Breast Cancer, (2025);32(6):1326-35.
Alasadi A, Fadhil N, Chen S. Deciphering the critical roles of the AMPK/mTOR signaling pathway in cancer cell metabolism. World Academy of Sciences Journal, (2025); 7: 103.
Daniele A, Divella R, Pilato B, Tommasi S, Pasanisi P, et al. The role of circulating adiponectin and SNP276G>T at ADIPOQ gene in BRCA-mutant women. Cancer Genomics & Proteomics, (2020); 17: 301-7.
Zhang Y, Song M, Yang Z, Huang X, Lin Y, et al. Healthy lifestyles, systemic inflammation and breast cancer risk: a mediation analysis. BMC cancer, (2024); 24(1):208.
Ekemen S, Bilir E, Soultan HE, Zafar S, Demir F, et al. The programmed cell death ligand 1 and lipocalin 2 expressions in primary breast cancer and their associations with molecular subtypes and prognostic factors. Breast Cancer: Targets and Therapy, (2024);1-3.
Veyssière H, Bidet Y, Penault-Llorca F, Radosevic-Robin N, Durando X. Circulating proteins as predictive and prognostic biomarkers in breast cancer. Clinical Proteomics, (2022); 19: 25.
Mogharnasi M, Taheri Chadorneshin H, Abbasi-Deloei N. Effect of exercise training type on plasma levels of vaspin, nesfatin-1, and high-sensitivity C-reactive protein in overweight and obese women. Obesity Medicine, (2019); 13: 34-8.
DOI: https://doi.org/10.62940/als.v13i4.4189
Refbacks
- There are currently no refbacks.